1 Maes M., "monocyte-T-lymphocyte hypothesis of major depression" 20 : 111-116, 1995
2 Cserr HF., "ervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view" 13 : 507-512, 1992
3 Beattie EC., "Von Zastrow M, et al. Control of synaptic strength by glial TNFalpha" 295 : 2282-2285, 2002
4 Xia Z., "Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells" 34 : 27-37, 1996
5 Capuron L., "Treatment of cytokine-induced depression" 16 : 575-580, 2002
6 Munoz-Fernandez MA., "The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system" 56 : 307-340, 1998
7 Licinio J., "The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection" 4 : 317-327, 1999
8 Kim YK., "The role of cytokine network in psychological stress" 15 : 148-155, 2003
9 Lee KM, "The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder" 6 : 1298-1304, 2006
10 Kasper S., "The rationale for long-term antidepressant therapy" 8 : 225-235, 1993
11 Kim YK., "The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs" 7 : 1107-1114, 2002
12 Smith RS, "The macrophage theory of depression" 35 : 298-306, 1991
13 Tracey KJ., "The inflammatory reflex" 420 : 853-859, 2002
14 Leonard BE, "The immune system, depression and the action of antidepressants" 25 : 767-780, 2001
15 Muller N., "The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine" 11 : 680-684, 2006
16 Schildkraut JJ., "The catecholamine hypothesis of affective disorders: a review of supporting evidence" 122 : 509-522, 1965
17 Camara EG., "The brain and the immune system: a psychosomatic network" 30 : 140-146, 1989
18 Myint AM, "Th1, Th2, and Th3 cytokine alterations in major depression" 88 : 167-173, 2005
19 Watanabe Y., "Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons" 588 : 341-345, 1992
20 Luine VN., "Steroid hormone influences on spatial memory" 743 : 201-211, 1994
21 Muller N., "Role of the cytokine network in the CNS and psychiatric disorders" 68 : 11-20, 1997
22 Nabriski D., "Role of corticotropin-releasing factor in immunosuppression" 104 : 238-247, 1991
23 Maes M., "Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression" 49 : 11-27, 1993
24 Charney DS, "Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression" 38 : 1160-1180, 1981
25 de Beaurepaire R., "Questions raised by the cytokine hypothesis of depression" 16 : 610-617, 2002
26 Ader R., "Psychoneuroimmunology: interactions between the nervous system and the immune system" 345 : 99-103, 1995
27 Solomon GF., "Psychoneuroimmunology: interactions between central nervous system and immune system" 18 : 1-9, 1987
28 Whyte EM., "Post stroke depression: epidemiology, pathophysiology, and biological treatment" 52 : 253-264, 2002
29 Young SN., "Pihl RO Ervin FR. Tryptophan depletion causes a rapid lowering of mood in normal males" 87 : 173-177, 1985
30 Gutman DA, "Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies" 79 : 471-478, 2003
31 Maes M., "Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion" 20 : 370-379, 1999
32 Meyers CA, "Mood and cognitive disorders in cancer patients receiving cytokine therapy" 461 : 75-81, 1999
33 Dantzer R., "Mechanisms of the behavioural effects of cytokines" 461 : 83-105, 1999
34 Maes M., "Major depression and activation of the inflammatory response system" 461 : 25-46, 1999
35 Pollmacher T., "Low levels of circulating inflammatory cytokines--do they affect human brain functions?" 16 : 525-532, 2002
36 Wong ML., "Localization of interleukin-1 beta converting enzyme mRNA in rat brain vasculature: evidence that the genes encoding the interleukin-1 system are constitutively expressed in brain blood vessels. Pathophysiological implications" 2 : 141-148, 1995
37 Myint AM., "Kynurenine pathway in major depression: evidence of impaired neuroprotection" 98 : 143-151, 2007
38 Neveu PJ., "Is there evidence for an effect of antidepressant drugs on immune function?" 461 : 267-281, 1999
39 Maier SF., "Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock" 695 : 279-282, 1995
40 Sluzewska A., "Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine" 762 : 474-476, 1995
41 Sapolsky R., "Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor" 238 : 522-524, 1987
42 Breder CD., "Interleukin-1 immunoreactive innervation of the human hypothalamus" 240 : 321-324, 1988
43 Suzuki E., "Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain" 215 : 201-204, 1996
44 Bauer J., "Induction of cytokine synthesis and fever suppresses REM sleep and improves mood in patients with major depression" 38 : 611-621, 1995
45 Wong ML., "Inducible nitric oxide synthase gene expression in the brain during systemic inflammation" 2 : 581-584, 1996
46 Maes M., "Increased serum interleukin-1-receptor-antagonist concentrations in major depression" 36 : 29-36, 1995
47 Guillemin GJ., "IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment" 21 : 1097-1101, 2001
48 Irwin MR., "Human psychoneuroimmunology: 20 years of discover" 22 : 129-139, 2008
49 Leonard BE., "HPA and immune axes in stress: involvement of the serotonergic system" 13 : 268-276, 2006
50 Maes M., "Evidence for an immune response in major depression: a review and hypothesis" 19 : 11-38, 1995
51 Shopsin B., "Enhancement of the antidepressant response to L-tryptophan by a liver pyrrolase inhibitor: a rational treatment approach" 4 : 188-192, 1978
52 Miller AH., "Effects of cytokines on glucocorticoid receptor expression and function" 461 : 107-116, 1999
53 Castanon N., "Effects of antidepressants on cytokine production and actions" 16 : 569-574, 2002
54 Myint AM, "Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression" 14 : 65-71, 2007
55 Lacroix S., "Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain" 70 : 452-466, 1998
56 Watkins LR., "Dynamic regulation of proinflammatory cytokines" 461 : 153-178, 1999
57 Kim YK, "Differences in cytokines between non-suicidal patients and suicidal patients in major depression" 32 : 356-361, 2008
58 Connor TJ., "Depression, stress and immunological activation: the role of cytokines in depressive disorders" 62 : 583-606, 1998
59 Stommel M., "Depression and functional status as predictors of death among cancer patients" 94 : 2719-2727, 2002
60 Edwards E., "Depression and Parkinson's disease: a new look at an old problem" 16 : 39-48, 2002
61 Anderson IM., "Decreased plasma tryptophan concentration in major depression: relationship to melancholia and weight loss" 20 : 185-191, 1990
62 Anisman H., "Cytokines, stress, and depressive illness" 16 : 513-524, 2002
63 Sakash JB., "Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection" 70 : 3959-3961, 2002
64 Maier SF., "Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition" 105 : 83-107, 1998
65 Rothwell NJ, "Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology" 69 : 85-95, 1996
66 Szelenyi J., "Cytokines and the central nervous system" 54 : 329-338, 2001
67 Schiepers OJ., "Cytokines and major depression" 29 : 201-217, 2005
68 Zalcman S., "Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6" 643 : 40-49, 1994
69 Myint AM, "Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression" 61 : 519-525, 2003
70 Pollak Y., "Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment" 5 : 389-399, 2002
71 Aloisi F., "Cytokine regulation of astrocyte function: in-vitro studies using cells from the human brain" 13 : 265-274, 1995
72 Weizman R., "Cytokine production in major depressed patients before and after clomipramine treatment" 35 : 42-47, 1994
73 Kim YK., "Cytokine imbalance in the pathophysiology of major depressive disorder" 31 : 1044-1053, 2007
74 Freidin M., "Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta" 89 : 10440-10443, 1992
75 Berkenbosch F., "Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1" 238 : 524-526, 1987
76 Leonard BE., "Changes in the immune system in rodent models of depression" 5 : 345-356, 2002
77 Leonard BE., "Changes in the immune system in depression and dementia: causal or co-incidental effects?" 19 : 305-312, 2001
78 Calogero AE., "Catecholamine effects upon rat hypothalamic corticotropin-releasing hormone secretion in vitro" 82 : 839-846, 1988
79 Mansbach RS., "Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist" 323 : 21-26, 1997